JP2024504364A - Ｇｃｎ２をモジュレートする化合物およびその使用 - Google Patents
Ｇｃｎ２をモジュレートする化合物およびその使用 Download PDFInfo
- Publication number
- JP2024504364A JP2024504364A JP2023544292A JP2023544292A JP2024504364A JP 2024504364 A JP2024504364 A JP 2024504364A JP 2023544292 A JP2023544292 A JP 2023544292A JP 2023544292 A JP2023544292 A JP 2023544292A JP 2024504364 A JP2024504364 A JP 2024504364A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- membered
- cancer
- optionally substituted
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Holo Graphy (AREA)
- Liquid Crystal Substances (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163140314P | 2021-01-22 | 2021-01-22 | |
| US63/140,314 | 2021-01-22 | ||
| PCT/US2022/013383 WO2022159746A1 (en) | 2021-01-22 | 2022-01-21 | Gcn2 modulating compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024504364A true JP2024504364A (ja) | 2024-01-31 |
| JP2024504364A5 JP2024504364A5 (enExample) | 2025-01-28 |
Family
ID=80446635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023544292A Pending JP2024504364A (ja) | 2021-01-22 | 2022-01-21 | Ｇｃｎ２をモジュレートする化合物およびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240083897A1 (enExample) |
| EP (1) | EP4281182A1 (enExample) |
| JP (1) | JP2024504364A (enExample) |
| KR (1) | KR20240021143A (enExample) |
| CN (1) | CN117203206A (enExample) |
| AU (1) | AU2022210760A1 (enExample) |
| BR (1) | BR112023014723A2 (enExample) |
| CA (1) | CA3209124A1 (enExample) |
| CO (1) | CO2023010940A2 (enExample) |
| CR (1) | CR20230408A (enExample) |
| IL (1) | IL304611A (enExample) |
| MX (1) | MX2023008589A (enExample) |
| PE (1) | PE20240691A1 (enExample) |
| WO (1) | WO2022159746A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202008749D0 (en) | 2020-06-09 | 2020-07-22 | Ip2Ipo Innovations Ltd | Novel compounds |
| WO2023230567A1 (en) * | 2022-05-25 | 2023-11-30 | Hibercell, Inc. | Gcn2 modulator for treating cancer |
| WO2024077092A1 (en) * | 2022-10-04 | 2024-04-11 | Hibercell, Inc. | Gcn2 inhibitor for treating metastases |
| IL322199A (en) * | 2023-01-20 | 2025-09-01 | Hibercell Inc | Crystalline forms of 6-(3-((5-chloro-2-methoxypyridine)-3-sulfonamido)-6,2-difluorophenyl)-N-methylimidazo[1, 5-A]pyrazine-1-carboxamide and methods of use are |
| WO2025122985A1 (en) * | 2023-12-08 | 2025-06-12 | Hibercell, Inc. | Methods of treating acute myeloid leukemia using combinations of gcn2 modulators, venetoclax, and azacitidine |
| WO2025137710A1 (en) * | 2023-12-22 | 2025-06-26 | Hibercell, Inc. | Methods of treating cancer using combinations of gcn2 modulators and belzutifan |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007508310A (ja) * | 2003-10-08 | 2007-04-05 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| JP2012512837A (ja) * | 2008-12-19 | 2012-06-07 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | プロテインキナーゼ阻害薬としての二環式ピラゾール |
| WO2018030466A1 (ja) * | 2016-08-10 | 2018-02-15 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2019148132A1 (en) * | 2018-01-29 | 2019-08-01 | Merck Patent Gmbh | Gcn2 inhibitors and uses thereof |
| WO2020210828A1 (en) * | 2019-04-12 | 2020-10-15 | Hibercell, Inc. | (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions |
| WO2021165346A1 (en) * | 2020-02-17 | 2021-08-26 | Black Belt Tx Ltd | Gcn2 modulator compounds |
-
2022
- 2022-01-21 BR BR112023014723A patent/BR112023014723A2/pt unknown
- 2022-01-21 KR KR1020237028260A patent/KR20240021143A/ko active Pending
- 2022-01-21 CA CA3209124A patent/CA3209124A1/en active Pending
- 2022-01-21 PE PE2023002158A patent/PE20240691A1/es unknown
- 2022-01-21 EP EP22704111.8A patent/EP4281182A1/en active Pending
- 2022-01-21 US US18/262,493 patent/US20240083897A1/en active Pending
- 2022-01-21 WO PCT/US2022/013383 patent/WO2022159746A1/en not_active Ceased
- 2022-01-21 MX MX2023008589A patent/MX2023008589A/es unknown
- 2022-01-21 JP JP2023544292A patent/JP2024504364A/ja active Pending
- 2022-01-21 CR CR20230408A patent/CR20230408A/es unknown
- 2022-01-21 AU AU2022210760A patent/AU2022210760A1/en active Pending
- 2022-01-21 CN CN202280022926.3A patent/CN117203206A/zh active Pending
-
2023
- 2023-07-20 IL IL304611A patent/IL304611A/en unknown
- 2023-08-22 CO CONC2023/0010940A patent/CO2023010940A2/es unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007508310A (ja) * | 2003-10-08 | 2007-04-05 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| JP2012512837A (ja) * | 2008-12-19 | 2012-06-07 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | プロテインキナーゼ阻害薬としての二環式ピラゾール |
| WO2018030466A1 (ja) * | 2016-08-10 | 2018-02-15 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2019148132A1 (en) * | 2018-01-29 | 2019-08-01 | Merck Patent Gmbh | Gcn2 inhibitors and uses thereof |
| WO2020210828A1 (en) * | 2019-04-12 | 2020-10-15 | Hibercell, Inc. | (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions |
| WO2021165346A1 (en) * | 2020-02-17 | 2021-08-26 | Black Belt Tx Ltd | Gcn2 modulator compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240021143A (ko) | 2024-02-16 |
| CA3209124A1 (en) | 2022-07-28 |
| CO2023010940A2 (es) | 2023-12-11 |
| CN117203206A (zh) | 2023-12-08 |
| BR112023014723A2 (pt) | 2023-10-03 |
| US20240083897A1 (en) | 2024-03-14 |
| CR20230408A (es) | 2024-05-07 |
| EP4281182A1 (en) | 2023-11-29 |
| IL304611A (en) | 2023-09-01 |
| WO2022159746A1 (en) | 2022-07-28 |
| AU2022210760A1 (en) | 2023-09-07 |
| MX2023008589A (es) | 2023-08-09 |
| PE20240691A1 (es) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109476664B (zh) | 作为自分泌运动因子抑制剂的新型化合物和包含其的药物组合物 | |
| JP2024504364A (ja) | Ｇｃｎ２をモジュレートする化合物およびその使用 | |
| TWI748539B (zh) | Cot調節劑及其使用方法 | |
| US20230192709A1 (en) | Fgfr inhibitors and methods of use thereof | |
| JP6133291B2 (ja) | ピラゾロ［３，４−ｃ］ピリジン化合物と使用方法 | |
| TW202214605A (zh) | 免疫調節劑、組合物及其方法 | |
| WO2019148005A1 (en) | Inhibitors of cbl-b and methods of use thereof | |
| JP2023538060A (ja) | 二環化合物、それを含む組成物、及びそれらの使用 | |
| WO2020210828A1 (en) | (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions | |
| CN110114343B (zh) | 吡唑并嘧啶化合物及其使用方法 | |
| KR20180002748A (ko) | 아미도-치환된 시클로헥산 유도체 | |
| TW202241873A (zh) | 用於治療與ｃｇａｓ相關的病症之化合物及組成物 | |
| WO2023091726A1 (en) | Inhibitors of cyclin‑dependent kinase 12 (cdk12) | |
| TW201726647A (zh) | 醫藥化合物 | |
| EP3888652A1 (en) | Heterocyclic compound | |
| AU2021265578A1 (en) | Azalactam compounds as HPK1 inhibitors | |
| JP2018502141A (ja) | キナゾリン及びキノリン化合物、ならびにその使用 | |
| JP2023516551A (ja) | 大環状ｒｉｐ２－キナーゼ阻害剤 | |
| US20240150345A1 (en) | Gcn2 modulating compounds and uses thereof | |
| TW202220990A (zh) | 雜芳基取代的螺哌啶基衍生物及其藥物用途 | |
| IL323942A (en) | Sarm1 modulators, preparations, and uses thereof | |
| WO2016139212A1 (en) | Triazolopyridine compounds and methods of use thereof | |
| WO2026035750A1 (en) | Inhibitors of akt and uses thereof | |
| WO2025106362A1 (en) | Ripk1 inhibitors and methods of use | |
| TW202542138A (zh) | 與含ｐａｔａｔｉｎ樣磷脂酶結構域蛋白３ＩＭ結合的化合物及其用於治療肝病之用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250120 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250120 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20251110 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251126 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260224 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260423 |